Effects of Renin-Angiotensin-Aldosterone Inhibitors on Early Outcomes of Hypertensive COVID-19 Patients : A Randomized Triple-Blind Clinical Trial
© The Author(s) 2021. Published by Oxford University Press on behalf of American Journal of Hypertension, Ltd. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
BACKGROUND: The role of angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) has been addressed in some studies related to the current coronavirus disease-2019 (COVID-19) pandemic with possible higher severity and mortality in patients with hypertension. A triple-blind randomized controlled trial was designed to evaluate the effects of these medications on the COVID-19 progression.
METHODS: Patients were enrolled in this trial between April and September 2020. They were randomized in 2 groups. The former dosage of ACEis/ARBs was continued in one group while in another group, the ACEis/ARBs were replaced by amlodipine ± carvedilol according to the dose equivalents. The primary outcomes were length of stay in hospitals and intensive care units (ICUs). Other outcomes include mechanical ventilation, noninvasive ventilation, readmission, and COVID-19 symptoms after discharge.
RESULTS: We randomized 64 patients with COVID-19 into 2 groups. Most patients were aged 66-80 and 46-65 years-old, 33 (51.6%) and 27 (42.2%), respectively. The study groups were nearly similar in baseline vital signs and characteristics. In addition, there was no significant difference in terms of recorded systolic and diastolic blood pressure measurements between groups. Furthermore, we did not find a significant difference between the days of ICU or ward admission, the discharge rate, or readmission rates between the 2 groups.
CONCLUSIONS: This randomized triple-blind multicentric clinical trial did not show any deleterious effects of ACEi/ARB medications in hypertensive COVID-19 patients.
CLINICAL TRIALS REGISTRATION: The trial acquired the ethical code, IR.TUMS.VCR.REC.1399.028 and was registered in the Iranian randomized controlled trial system (registration no. IRCT20151113025025N3), https://en.irct.ir/trial/46531.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
American journal of hypertension - 34(2021), 11 vom: 20. Nov., Seite 1217-1226 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Najmeddin, Farhad [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.10.2022 Date Revised 26.01.2023 published: Print IRCT: IRCT20151113025025N3 CommentIn: Am J Hypertens. 2021 Aug 18;:. - PMID 34406353 Citation Status MEDLINE |
|---|
| doi: |
10.1093/ajh/hpab111 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328105341 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328105341 | ||
| 003 | DE-627 | ||
| 005 | 20231225202237.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ajh/hpab111 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1093.xml |
| 035 | |a (DE-627)NLM328105341 | ||
| 035 | |a (NLM)34265044 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Najmeddin, Farhad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of Renin-Angiotensin-Aldosterone Inhibitors on Early Outcomes of Hypertensive COVID-19 Patients |b A Randomized Triple-Blind Clinical Trial |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.10.2022 | ||
| 500 | |a Date Revised 26.01.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a IRCT: IRCT20151113025025N3 | ||
| 500 | |a CommentIn: Am J Hypertens. 2021 Aug 18;:. - PMID 34406353 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2021. Published by Oxford University Press on behalf of American Journal of Hypertension, Ltd. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: The role of angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) has been addressed in some studies related to the current coronavirus disease-2019 (COVID-19) pandemic with possible higher severity and mortality in patients with hypertension. A triple-blind randomized controlled trial was designed to evaluate the effects of these medications on the COVID-19 progression | ||
| 520 | |a METHODS: Patients were enrolled in this trial between April and September 2020. They were randomized in 2 groups. The former dosage of ACEis/ARBs was continued in one group while in another group, the ACEis/ARBs were replaced by amlodipine ± carvedilol according to the dose equivalents. The primary outcomes were length of stay in hospitals and intensive care units (ICUs). Other outcomes include mechanical ventilation, noninvasive ventilation, readmission, and COVID-19 symptoms after discharge | ||
| 520 | |a RESULTS: We randomized 64 patients with COVID-19 into 2 groups. Most patients were aged 66-80 and 46-65 years-old, 33 (51.6%) and 27 (42.2%), respectively. The study groups were nearly similar in baseline vital signs and characteristics. In addition, there was no significant difference in terms of recorded systolic and diastolic blood pressure measurements between groups. Furthermore, we did not find a significant difference between the days of ICU or ward admission, the discharge rate, or readmission rates between the 2 groups | ||
| 520 | |a CONCLUSIONS: This randomized triple-blind multicentric clinical trial did not show any deleterious effects of ACEi/ARB medications in hypertensive COVID-19 patients | ||
| 520 | |a CLINICAL TRIALS REGISTRATION: The trial acquired the ethical code, IR.TUMS.VCR.REC.1399.028 and was registered in the Iranian randomized controlled trial system (registration no. IRCT20151113025025N3), https://en.irct.ir/trial/46531 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a adverse outcome | |
| 650 | 4 | |a angiotensin receptor antagonists | |
| 650 | 4 | |a angiotensin-converting enzyme inhibitors | |
| 650 | 4 | |a blood pressure | |
| 650 | 4 | |a coronavirus disease-2019 | |
| 650 | 4 | |a hypertension | |
| 650 | 7 | |a Angiotensin Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Angiotensins |2 NLM | |
| 650 | 7 | |a Antihypertensive Agents |2 NLM | |
| 650 | 7 | |a Mineralocorticoid Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Carvedilol |2 NLM | |
| 650 | 7 | |a 0K47UL67F2 |2 NLM | |
| 650 | 7 | |a Amlodipine |2 NLM | |
| 650 | 7 | |a 1J444QC288 |2 NLM | |
| 650 | 7 | |a Aldosterone |2 NLM | |
| 650 | 7 | |a 4964P6T9RB |2 NLM | |
| 650 | 7 | |a Renin |2 NLM | |
| 650 | 7 | |a EC 3.4.23.15 |2 NLM | |
| 700 | 1 | |a Solhjoo, Maedeh |e verfasserin |4 aut | |
| 700 | 1 | |a Ashraf, Haleh |e verfasserin |4 aut | |
| 700 | 1 | |a Salehi, Mohammadreza |e verfasserin |4 aut | |
| 700 | 1 | |a Rasooli, Fatemeh |e verfasserin |4 aut | |
| 700 | 1 | |a Ghoghaei, Morteza |e verfasserin |4 aut | |
| 700 | 1 | |a Soleimani, Abbas |e verfasserin |4 aut | |
| 700 | 1 | |a Bahreini, Maryam |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of hypertension |d 1988 |g 34(2021), 11 vom: 20. Nov., Seite 1217-1226 |w (DE-627)NLM012611670 |x 1941-7225 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2021 |g number:11 |g day:20 |g month:11 |g pages:1217-1226 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ajh/hpab111 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2021 |e 11 |b 20 |c 11 |h 1217-1226 | ||